Patients with adverse‐risk AML were less likely to enter cCR than those with non‐adverse risk (76% vs 98%, P = 0.009), whereas FLT3 mutation status did not impact cCR attainment (95% FLT3‐mutated vs 90% FLT3 wild‐type, P = 0.525; Fig. 2). The gene discussed is FLT3; the disease is acute myeloid leukemia.